Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923474 | 1.00 | CYP11B1 (0.42) | CYP11B1CYP11B2IDO1MIFNPC1 | |
| SCHEMBL31082541 | 0.85 | MAPK1 (0.42) | IDO1NPC1LMNAALDH1A1POLB | |
| SCHEMBL4309645 | 0.80 | CYP11B1 (0.46) | CYP11B1CYP11B2IDO1MIF | |
| SCHEMBL20437053 | 0.78 | DDB1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL14911768 | 0.75 | IDO1 (0.40) | IDO1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14911616 | 0.74 | ALOX12 (0.50) | CYP11B2IDO1RAB9A | |
| SCHEMBL22552462 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL29480933 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL28916765 | 0.73 | G6PD (0.45) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL28590872 | 0.73 | JAK2 (0.48) | IDO1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CYP11B1 18/4885CYP11B2 30/4885IDO1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.